Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 3;10(12):1940. doi: 10.3390/antiox10121940

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

SOD-1 intracellular content in T cells identified two sub-groups of MS-RR individuals undergoing immune-modulating therapy, except fingolimod. (A) Analysis of SOD-1 distribution in T lymphocytes of MS-RR subjects undergoing all treatments, but fingolimod; as shown, Group 1 is MS-RR subjects characterized by SOD-1 intracellular content in T cells similar to healthy individuals (light grey box; SOD-1 MIF fold increase vs. isotype control <10); Group 2 is MS-RR subjects characterized by SOD-1 intracellular content in T cells significantly higher than healthy individuals (dark grey box; SOD-1 MIF fold increase vs. isotype control >10). (B,D,F,H) Percentage of circulating CD3⁺, iNKT, NK, and B lymphocytes, respectively. (C,E,G,I) Numbers of CD3⁺, iNKT, NK, and B lymphocytes, respectively. (J) CD4⁺/CD8⁺ ratio. Statistical evaluation of data, was performed by means of the Mann–Whitney test.